Patents by Inventor David Azorsa

David Azorsa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SIRNA CONSTRUCTS FOR INHIBITING GENE EXPRESSION IN TARGETED CANCER CELLS
    Publication number: 20240240178
    Abstract: The invention provides siRNA compositions for inhibiting gene expression in targeted cells. A multi-targeting siR-NA-aptamer platform is provided that is efficiently delivered and is processed by cellular RNAi machinery to produce one, two or more siRNAs. Methods of using the multi-targeting siRNA-aptamer for selectively targeting cancer cells to downregulate the expression of multiple genes are also provided.
    Type: Application
    Filed: May 5, 2022
    Publication date: July 18, 2024
    Inventors: Spyro Mousses, David Azorsa, Daniel Feldheim, James Heil, Necky Tran, Gregory Allen Penner
  • MULTITARGETING RNA COMPOSITIONS
    Publication number: 20240240177
    Abstract: The invention provides siRNA compositions for inhibiting gene expression in targeted cells.
    Type: Application
    Filed: May 5, 2022
    Publication date: July 18, 2024
    Inventors: Spyro Mousses, David Azorsa, Daniel Feldheim, James Heil, Necky Tran, Gregory Allen Penner
  • Compositions for Inhibiting Growth of Targeted Cells
    Publication number: 20240229033
    Abstract: The invention provides siRNA compositions for inhibiting gene expression in targeted cells.
    Type: Application
    Filed: May 5, 2022
    Publication date: July 11, 2024
    Inventors: Spyro Mousses, David Azorsa, Daniel Feldheim, James Heil, Necky Tran, Gregory Allen Penner
  • Multitargeting RNA Immunotherapy Compositions
    Publication number: 20240229032
    Abstract: A multi-targeting siRNA-aptamer platform is provided that is processed by cellular RNAi machinery to produce siR-NAs. The constructs according to the invention are targeted at cells of the immune system. Methods of using the multi-targeting siR-NA-aptamer for selectively targeting cells to down-regulate the expression of multiple genes are also provided.
    Type: Application
    Filed: May 5, 2022
    Publication date: July 11, 2024
    Inventors: Spyro Mousses, David Azorsa, Daniel Feldheim, James Heil, Necky Tran, Gregory Allen Penner
  • Hybridoma clones and monoclonal antibodies to CD9
    Patent number: 9862773
    Abstract: The present invention is directed to a monoclonal antibody that recognizes human CD9 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and exosome isolation kits using the antibody.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 9, 2018
    Assignee: The Translational Genomics Research Institute
    Inventor: David Azorsa
  • Hybridoma clones and monoclonal antibodies to tetraspanin 8
    Patent number: 9850303
    Abstract: The present invention is directed to a monoclonal antibody that recognizes human TSPAN8 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and exosome purification kits using the antibody.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: December 26, 2017
    Assignee: The Translational Genomics Research Institute
    Inventor: David Azorsa
  • Hybridoma clones, monoclonal antibodies, and methods of use
    Patent number: 9738717
    Abstract: The present invention is directed to a monoclonal antibody that recognizes human CD63 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and to methods of diagnosing and treating cancer and purifying exosomes using the antibody. The invention is further directed to pharmaceutical compositions comprising an antibody of the invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: August 22, 2017
    Assignee: The Translational Genomics Research Institute
    Inventor: David Azorsa
  • Hybridoma clones and monoclonal antibodies to fibroblast growth factor 4
    Patent number: 9611319
    Abstract: The present invention is directed to a monoclonal antibody that recognizes human FGFR4 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody and methods of use thereof.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 4, 2017
    Assignee: The Translational Genomics Research Institute
    Inventor: David Azorsa
  • Hybridoma Clones, Monoclonal Antibodies, and Methods of Use
    Publication number: 20160115229
    Abstract: The present invention is directed to a monoclonal antibody that recognizes human CD63 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and to methods of diagnosing and treating cancer and purifying exosomes using the antibody. The invention is further directed to pharmaceutical compositions comprising an antibody of the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 15, 2013
    Publication date: April 28, 2016
    Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INTSITUTE
    Inventor: David Azorsa
  • Hybridoma Clones and Monoclonal Antibodies to Tetraspanin 8
    Publication number: 20160039931
    Abstract: The present invention is directed to a monoclonal antibody that recognizes human TSPAN8 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and exosome purification kits using the antibody.
    Type: Application
    Filed: March 17, 2014
    Publication date: February 11, 2016
    Applicant: The Translational Genomics Research Intsitute
    Inventor: David AZORSA
  • Hybridoma Clones and Monoclonal Antibodies to CD9
    Publication number: 20160032002
    Abstract: The present invention is directed to a monoclonal antibody that recognizes human CD9 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and exosome isolation kits using the antibody.
    Type: Application
    Filed: March 17, 2014
    Publication date: February 4, 2016
    Applicant: The Translational Genomics Research Institute
    Inventor: David Azorsa
  • Hybridoma Clones and Monoclonal Antibodies to Fibroblast Growth Factor 4
    Publication number: 20160017027
    Abstract: The present invention is directed to a monoclonal antibody that recognizes human FGFR4 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody and methods of use thereof.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 21, 2016
    Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventor: David Azorsa
  • Compositions and methods for prognosis, diagnosis, prevention and treatment of cancers
    Publication number: 20050196796
    Abstract: The present invention provides compositions and methods of using the EPHB2 gene or its related signaling pathways to detect, prognosticate, assess the risk of, prevent, or treat cancers. Cancers amenable to the present invention include, but are not limited to, prostate cancer, breast cancer, and neuroblastoma. In one aspect, the present invention provides compositions which comprise an agent capable of eradicating or alleviating an abnormality in the EPHB2 gene or its related signaling pathways. This abnormality may cause or contribute to the development or progression of cancers. In another aspect, the present invention provides methods comprising detecting an abnormality in the EPHB2 gene or its related signaling pathways. The presence or absence of such an abnormality is indicative of the risk or disease status of cancer in a person of interest.
    Type: Application
    Filed: February 24, 2005
    Publication date: September 8, 2005
    Applicant: Translational Genomics Research
    Inventors: Spyro Mousses, Pia Huusko, Olli-P Kallioniemi, John Carpten, David Azorsa, Jeffrey Kiefer